BioNTech SE (BNTX) fair value analysis
Nasdaq · Updated 2026-10-19
BNTX price how computed
Valuation status
Reports in EURBNTX reports its results in EUR while its shares trade in US dollars.
Forward Fair Value needs earnings and price in the same currency, so TickrTrends publishes no fair-value verdict for BNTX until same-currency inputs are available. Price and market cap below are in US dollars; revenue and EPS are shown in EUR.
- Last price
- $96.85
- Sector
- Healthcare
- 12-month range
- $83.89–$119.34
- Market cap
- $24.3B
- From 52-week high
- -18.8%
- Shares outstanding
- 251M
- Rank in Healthcare by quality score
- #127 of 301
Last price is the 2026-10-01 month-start close, the freshest stored price; the chart runs through 2026-10-16.
BioNTech SE is a German biotechnology company that develops immunotherapies and vaccines, with a focus on personalized medicine and infectious disease prevention. The company operates research and manufacturing facilities in Europe and maintains a global presence through partnerships and operations across multiple continents.
BNTX currently ranks #127 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
Revenue and EPS are shown in EUR; the trailing P/E is omitted because an EPS in EUR against a US-dollar share price would mislead.
- Market cap
- $24.3B
- Revenue (TTM)
- EUR 2.64B
- Net margin
- -64.0%
- EPS (TTM)
- EUR -5.43
- Gross margin
- 8.1%
- Debt / equity
- 0.02
- Revenue growth (3-yr avg)
- -29.4%
- Shares outstanding
- 251M
Derived indicators how computed
- Quality grade
- D
- Margin trend
- Contracting
- 52-week position
- The lower-middle quarter of its range
Technicals how computed
- RSI (14-day)
- 34 · neutral
- 50-day average
- $98.78
- 200-day average
- $97.68
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Dividends how computed
- Dividend
- None in the last 12 months (last ex-date 2022-06-02)
Earnings how computed
- Next earnings report
- 2026-11-03 (pre-market)
- Last 8 quarters vs consensus
- 3 beat, 5 missed
- Quarter by quarter
- 2026-06 ▼ miss (-17.4%)
2026-03 ▼ miss (-1.6%)
2025-12 ▼ miss (-33.5%)
2025-09 ▼ miss (-220.0%)
2025-06 ▼ miss (-13.5%)
2025-03 ▲ beat (+26.4%)
2024-12 ▲ beat (+126.6%)
2024-09 ▲ beat (+150.3%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 14 buy · 5 hold · 1 sell (20 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $117
- Target vs last price
- +20.8%
What our data shows for BNTX
- Shares are trading in the middle of their 12-month price range of $83.89–$119.34.
- The 14-day relative strength index sits at a neutral 34.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- BNTX's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent BNTX news
TickrTrends' derived news-sentiment signal for BNTX is currently leaning negative, computed from recent coverage.
- BioNTech's BNT113 Combo Vaccine Misses Key Progression-Free Survival Goal, Shares Reflect Mixed Outlook (BNTX) (gurufocus.com, 2026-10-13)
- BioNTech (BNTX) Shares Drop After Phase 2/3 Trial Misses Primary Endpoint in Head and Neck Cancer Study (gurufocus.com, 2026-10-13)
- Citi Maintains Buy on BioNTech (BNTX) Despite BNT113 Trial Setback (gurufocus.com, 2026-10-13)
What people are saying
Follow the BNTX conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — BNTX's quality grade improved from F to D this week according to TickrTrends' derived indicators. The stock remains in the Healthcare sector with a valuation verdict of awaiting full valuation.
- 2026-10-05 — TickrTrends' derived indicators for BNTX showed a shift this week as the 50/200-day trend state moved from uptrend to mixed, reflecting a change in the near-term momentum relative to longer-term price direction. The stock remains in the Healthcare sector with a valuation verdict currently awaiting full valuation assessment.
- 2026-09-28 — BNTX's 50/200-day trend state has shifted from mixed to uptrend this week, indicating that shorter-term price momentum has aligned with longer-term directional movement. The Healthcare sector company's derived indicator positioning reflects this technical improvement, though the current valuation verdict remains awaiting full valuation pending additional data.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is BNTX stock undervalued?
BNTX reports its results in EUR while its shares trade in US dollars. Forward Fair Value needs earnings and price in the same currency, so TickrTrends publishes no fair-value verdict for BNTX until same-currency inputs are available.
What is BNTX's TickrTrends verdict?
BNTX is currently marked 'Reports in EUR' - no verdict is published on inputs in two different currencies.
How does BNTX compare to other Healthcare stocks?
BNTX ranks #127 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is BNTX overbought or oversold?
BNTX's 14-day RSI is in neutral territory - neither overbought nor oversold.
Does BNTX pay a dividend?
BNTX has paid no dividend in the last twelve months; its last ex-dividend date on file was 2022-06-02.
When does BNTX report earnings next?
BNTX's next earnings report is scheduled for 2026-11-03 (pre-market), per the published earnings calendar.
Does BNTX usually beat earnings estimates?
Over its last 8 reported quarters BNTX beat the consensus estimate 3 times and missed 5 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about BNTX?
Of 20 analysts covering BNTX, 14 rate it a buy, 5 a hold and 1 a sell - buy-leaning, with a consensus price target of $117 (+20.8% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.